Related Experiment Video
Updated: Jan 29, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center
Filiz Yucebay1, Christina Matthews2, Marcin Puto1
1Department of Pharmacy, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center , Columbus , Ohio , 43210 , USA.
Abstract:
Acute graft-versus-host-disease (aGVHD) is a complication after allogeneic stem cell transplant. After the failure of treatment with high dose corticosteroids, steroid-refractory aGVHD (SR aGVHD) is associated with high rates of mortality. Tocilizumab has evidence of activity in SR aGVHD. For patients ineligible for trials, the OSU James Comprehensive Cancer Center has been utilizing tocilizumab as first-line therapy for SR aGVHD. We retrospectively report on 15 patients who received tocilizumab. aGVHD grading and responses were based on consensus criteria. Median age at transplant was 49 years. Median time to tocilizumab administration was 9 days (range, 3-16). Six patients had complete responses (40%) with a resolution of aGVHD. From the last contact, median overall survival for responders was not yet reached vs. 31 days for non-responders (p = .0002). Patients with skin and/or GI aGVHD demonstrated the greatest benefit. Patients with liver aGVHD did not respond. Future studies are needed to evaluate tocilizumab prior to steroid failure.
Related Concept Videos
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Gene Therapy
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...
Center of Mass
The knowledge of the center of mass can also help us to describe and predict the motion of objects. For example, when a ball is thrown...
What is an Experiment?

